JP2013540123A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540123A5
JP2013540123A5 JP2013531826A JP2013531826A JP2013540123A5 JP 2013540123 A5 JP2013540123 A5 JP 2013540123A5 JP 2013531826 A JP2013531826 A JP 2013531826A JP 2013531826 A JP2013531826 A JP 2013531826A JP 2013540123 A5 JP2013540123 A5 JP 2013540123A5
Authority
JP
Japan
Prior art keywords
respirable dry
dry powder
particles
dry particles
respirable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013531826A
Other languages
English (en)
Other versions
JP2013540123A (ja
JP5877204B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2011/049435 external-priority patent/WO2012030664A1/en
Application filed filed Critical
Priority claimed from PCT/US2011/053829 external-priority patent/WO2012044736A1/en
Publication of JP2013540123A publication Critical patent/JP2013540123A/ja
Publication of JP2013540123A5 publication Critical patent/JP2013540123A5/ja
Application granted granted Critical
Publication of JP5877204B2 publication Critical patent/JP5877204B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (20)

  1. a)1種以上の一価金属カチオン塩、ここで、前記1種以上の一価金属カチオン塩が、乾燥粒子の少なくとも約3重量%の量で存在する、および
    b)薬学的活性剤、ここで、前記薬学的活性剤が、抗生物質、LABA、LAMA、コルチコステロイド、またはそれらの任意の組み合わせである、
    を含む呼吸可能乾燥粒子を含む呼吸可能乾燥粉末であって、前記呼吸可能乾燥粒子が、レーザ回折(RODOS/HELOSシステム)により測定されると約10ミクロン以下の体積中位幾何学径(VMGD)および約1.5未満の分散可能性比(1バール/4バール)を有前記呼吸可能乾燥粒子は、0.45g/cc〜1.2g/ccのタップ密度を有し、但し、前記呼吸可能乾燥粒子が、二価金属カチオンを前記乾燥粒子の3重量%以上の量で含有しない、呼吸可能乾燥粉末。
  2. 呼吸可能乾燥粒子が、二価金属カチオン塩を前記乾燥粒子の5重量%以上の量で含有しないことを更なる条件とする、請求項1に記載の呼吸可能乾燥粉末。
  3. 前記呼吸可能乾燥粒子が、約5.0ミクロン以下の体積中位幾何学径(VMGD)を有する、請求項1または2に記載の呼吸可能乾燥粉末。
  4. 少なくとも45%の、5.6ミクロン未満の細粒分(FPF)を有する、請求項1または2に記載の呼吸可能乾燥粉末。
  5. 約5ミクロン以下の質量中位空気力学径(MMAD)を有する、請求項1または2に記載の呼吸可能乾燥粉末。
  6. 少なくとも1種の薬学的に許容し得る賦形剤を更に含む、請求項1または2に記載の呼吸可能乾燥粉末。
  7. 少なくとも1種の賦形剤が、ロイシン、マルトデキストリン、マンニトールおよびそれらの組み合わせからなる群より選択される、請求項に記載の呼吸可能乾燥粉末。
  8. 前記一価金属カチオン塩が、ナトリウム塩である、請求項1または2に記載の呼吸可能乾燥粉末。
  9. 前記ナトリウム塩が、塩化ナトリウム、乳酸ナトリウム、クエン酸ナトリウム、硫酸ナトリウムまたはそれらの組み合わせである、請求項に記載の呼吸可能乾燥粉末。
  10. 前記一価金属カチオン塩が、カリウム塩である、請求項1または2に記載の呼吸可能乾燥粉末。
  11. 前記粉末のタップ密度が、0.55g/ccを超える、請求項1または2に記載の呼吸可能乾燥粉末。
  12. a)1種以上の一価金属カチオン塩、ここで、前記1種以上の一価金属カチオン塩が、乾燥粒子の少なくとも約3重量%の量で存在する、および
    b)薬学的活性剤、ここで、前記薬学的活性剤が、高分子である、
    を含む、呼吸可能乾燥粒子を含む呼吸可能乾燥粉末であって、前記呼吸可能乾燥粒子が、レーザ回折(RODOS/HELOSシステム)により測定されると約10ミクロン以下の体積中位幾何学径(VMGD)および約1.5未満の分散可能性比(1バール/4バール)を有し、前記呼吸可能乾燥粒子は、0.45g/cc〜1.2g/ccのタップ密度を有し、但し、前記呼吸可能乾燥粒子が、二価金属カチオンを前記乾燥粒子の3重量%以上の量で含有しない、呼吸可能乾燥粉末。
  13. 薬学的活性剤が、抗体、ホルモン、および増殖因子からなる群より選択される、請求項12に記載の呼吸可能乾燥粉末。
  14. 一価の塩、ここで、前記一価の塩がナトリウム塩である、
    活性剤、ここで、前記活性剤がLAMAである、および
    賦形剤
    を含む呼吸可能乾燥粒子を含む呼吸可能乾燥粉末であって、前記ナトリウム塩が、塩化ナトリウムであり、かつ約60%〜約99%の量であり、前記LAMAが、チオトロピウムであり、かつ約0.01%〜約10%の量であり、前記賦形剤が、ロイシンであり、かつ約50%以下の量であり、全ての重量による%が乾燥粒子の重量に従い、前記呼吸可能乾燥粉末が、HELOS/RODOSシステムを用いて測定する場合1バールで0.5ミクロン〜10ミクロンのVMGD、1.5未満の1バール/4バール、および約0.4g/cm 〜約1.2g/cm のタップ密度を特徴とする呼吸可能乾燥粒子を含む、呼吸可能乾燥粉末。
  15. 吸器疾患の治療のための医薬の製造における、請求項1、2、12、13または14に記載の呼吸可能乾燥粉末の使用
  16. 吸器疾患の急性増悪の治療または予防のための医薬の製造における、請求項1、2、12、13または14に記載の呼吸可能乾燥粉末の使用
  17. 吸管の感染性疾患の治療または予防のための医薬の製造における、請求項1、2、12、13または14に記載の呼吸可能乾燥粉末の使用
  18. 前記呼吸器疾患が、喘息、気道過敏性、季節性アレルギー、気管支拡張症、慢性気管支炎、気腫、慢性閉塞性肺疾患または嚢胞性線維症である、請求項15に記載の使用
  19. 呼吸可能乾燥粒子が、以下の条件:前記呼吸可能乾燥粒子で少なくとも10%が満たされたサイズ3カプセルを使用して約2ジュール未満の総吸入エネルギー下で受動式乾燥粉末吸入器から放出される場合、少なくとも80%のカプセル放出粉末質量(CEPM)を更に特徴とする、請求項1、2、12、13または14に記載の呼吸可能乾燥粉末。
  20. 前記呼吸可能乾燥粉末が、以下の条件:前記呼吸可能乾燥粒子からなる20mgの全重量を含むサイズ3カプセルを使用して30リットル/分(LPM)の流速で約1.2ジュール未満の総吸入エネルギー下で約0.036kPa 1/2 /LPMの抵抗を有する受動式乾燥粉末吸入器から放出した場合、5マイクロメータ未満の幾何学的サイズ(Dv50)を更に特徴とする、請求項1、2、12、13または14に記載の呼吸可能乾燥粉末。
JP2013531826A 2010-09-29 2011-09-29 吸入用の一価金属カチオン乾燥粉末 Active JP5877204B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38788310P 2010-09-29 2010-09-29
US61/387,883 2010-09-29
US201161481879P 2011-05-03 2011-05-03
US61/481,879 2011-05-03
USPCT/US2011/049435 2011-08-26
PCT/US2011/049435 WO2012030664A1 (en) 2010-08-30 2011-08-26 Dry powder formulations and methods for treating pulmonary diseases
PCT/US2011/053829 WO2012044736A1 (en) 2010-09-29 2011-09-29 Monovalent metal cation dry powders for inhalation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016011411A Division JP6186458B2 (ja) 2010-09-29 2016-01-25 吸入用の一価金属カチオン乾燥粉末

Publications (3)

Publication Number Publication Date
JP2013540123A JP2013540123A (ja) 2013-10-31
JP2013540123A5 true JP2013540123A5 (ja) 2014-11-06
JP5877204B2 JP5877204B2 (ja) 2016-03-02

Family

ID=45002202

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013531826A Active JP5877204B2 (ja) 2010-09-29 2011-09-29 吸入用の一価金属カチオン乾燥粉末
JP2016011411A Active JP6186458B2 (ja) 2010-09-29 2016-01-25 吸入用の一価金属カチオン乾燥粉末
JP2017148309A Active JP6392422B2 (ja) 2010-09-29 2017-07-31 吸入用の一価金属カチオン乾燥粉末

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016011411A Active JP6186458B2 (ja) 2010-09-29 2016-01-25 吸入用の一価金属カチオン乾燥粉末
JP2017148309A Active JP6392422B2 (ja) 2010-09-29 2017-07-31 吸入用の一価金属カチオン乾燥粉末

Country Status (12)

Country Link
US (6) US9642798B2 (ja)
EP (2) EP2621484A1 (ja)
JP (3) JP5877204B2 (ja)
KR (2) KR20180122475A (ja)
CN (2) CN107096014B (ja)
AU (2) AU2011308865B2 (ja)
BR (1) BR112013007304B1 (ja)
CA (2) CA2812414C (ja)
IL (4) IL286573B (ja)
MX (1) MX354828B (ja)
RU (2) RU2017144619A (ja)
WO (1) WO2012044736A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
IL286573B (en) * 2010-09-29 2022-08-01 Pulmatrix Operating Co Inc Monovalent metallic cation dry powders for inhalation
WO2013130767A1 (en) * 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
US9044035B2 (en) * 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
GB201215988D0 (en) * 2012-09-07 2012-10-24 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical compositions comprising flurbiprofen
CN105324106A (zh) * 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
EP3203985A1 (en) * 2014-10-08 2017-08-16 Pulmatrix Operating Company, Inc. Improved stability of dry powders containing tiotropium and amino acid
US20170304197A1 (en) * 2014-10-08 2017-10-26 Pulmatrix Operating Company, Inc. Formulations containing tiotropium, amino acid and acid and methods thereof
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
US10046007B2 (en) 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
PT108885B (pt) 2015-10-12 2019-02-13 Hovione Farm S A Método de produção de partículas compósitas inaláveis mediante a utilização de um atomizador de três fluidos
MX2018009159A (es) * 2016-01-29 2019-06-13 Mannkind Corp Inhalador de polvo seco.
CN106116561B (zh) * 2016-06-28 2018-10-12 南通众兴磁业有限公司 永磁铁氧体磁性材料
EA201991096A1 (ru) 2016-10-31 2019-09-30 Вектура Лимитед Ингалируемая порошковая композиция, содержащая анти-il-13-антитело
EP3760189A4 (en) * 2018-02-26 2022-01-05 Shin Nippon Biomedical Laboratories, Ltd. PULVERULENT PREPARATION, CARTRIDGE AND DEVICE
CN110161142A (zh) * 2019-06-11 2019-08-23 珠海瑞思普利生物制药有限公司 一种表征干粉吸入制剂在呼吸系统空气动力学的仿真装置
WO2021012044A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
WO2021202429A1 (en) * 2020-03-28 2021-10-07 Esrail Medical Corp. Methods and compositions for treatment of covid-19
JP2023544638A (ja) * 2020-10-09 2023-10-24 リウ、チー 吸入製剤及びその製造方法と使用
US20220151920A1 (en) * 2020-11-18 2022-05-19 Bend Research, Inc. Inhalable dry powder formulations comprising angiogenesis inhibitors
WO2024046582A1 (en) * 2022-09-02 2024-03-07 Liita Care Aps Pharmaceutical dry powder composition and methods for treating respiratory tract infections

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1575050A1 (de) 1966-01-12 1972-04-13 Misto Gen Equipment Co Ultraschall-Nebelerzeugungsgeraet
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4085893A (en) 1974-03-20 1978-04-25 Durley Iii Benton A Ultrasonic humidifiers, atomizers and the like
US4193009A (en) 1976-01-26 1980-03-11 Durley Benton A Iii Ultrasonic piezoelectric transducer using a rubber mounting
JPS5550437U (ja) 1978-09-28 1980-04-02
US4233405A (en) 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
DE3229179C2 (de) 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
KR900001873B1 (ko) 1984-06-14 1990-03-26 산요덴끼 가부시끼가이샤 초음파 가습장치
US4637815A (en) 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
FI82808C (fi) 1987-12-31 1991-04-25 Etelae Haemeen Keuhkovammayhdi Ultraljudfinfoerdelningsanordning.
US5511726A (en) 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US4899914A (en) 1988-11-04 1990-02-13 Ciba-Geigy Corporation Method for producing a sterile preservative-free aerosol saline solution
US4921639A (en) 1988-11-09 1990-05-01 Bernard Chiu Ultrasonic humidifier
US4881541A (en) 1988-12-21 1989-11-21 The Regents Of The University Of California Vaporizer for an anesthetic having a vapor pressure about one atmosphere
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
US5571535A (en) 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
JPH05123398A (ja) 1991-11-06 1993-05-21 Tsunemasa Kamiyama 咽喉保護吸入剤並びに吸入器具
GB2265845B (en) 1991-11-12 1996-05-01 Medix Ltd A nebuliser and nebuliser control system
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
JP3961029B2 (ja) 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5292127C1 (en) * 1992-10-02 2001-05-22 Arcade Planet Inc Arcade game
US5898037A (en) 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
US6098620A (en) 1993-01-29 2000-08-08 Aradigm Corporation Device for aerosolizing narcotics
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
NZ328476A (en) 1993-06-24 1999-05-28 Astra Ab Use of a two component insulin preparation in an inhalation device
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
ATE218132T1 (de) 1994-10-14 2002-06-15 Yamanouchi Pharma Co Ltd Azol-derivate
US5863563A (en) 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
SK284448B6 (sk) 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Merací dávkovací inhalátor
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JP3708553B2 (ja) 1995-04-14 2005-10-19 ネクター セラピューティクス 向上した分散性を有する粉末型薬理組成物
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
RU2140273C1 (ru) * 1996-11-06 1999-10-27 Закрытое акционерное общество "АЭРОМЕД" Способ лечения простудных заболеваний
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US5881720A (en) 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
DE69814428T2 (de) 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
CA2327670A1 (en) 1998-04-08 1999-10-14 Darrel Lavern Allen Pulmonary and nasal delivery of raloxifene
US5883084A (en) 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
FR2780285B1 (fr) 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
JP3312216B2 (ja) 1998-12-18 2002-08-05 オムロン株式会社 噴霧装置
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
ES2228467T3 (es) 1999-02-03 2005-04-16 Biosante Pharmaceuticals, Inc. Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso.
EP1173245B1 (en) 1999-05-03 2004-09-01 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU763041B2 (en) * 1999-08-25 2003-07-10 Alkermes, Inc. Modulation of release from dry powder formulations
JP2003507411A (ja) 1999-08-25 2003-02-25 アドバンスト インハレーション リサーチ,インコーポレイテッド 噴霧乾燥大多孔性粒子製剤
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
MXPA02004193A (es) 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
AU772096B2 (en) 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6637432B2 (en) 2000-05-09 2003-10-28 Iep Pharmaceutical Devices Inc. Inhalation actuated device
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
WO2002000197A1 (en) 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6669959B1 (en) 2000-07-18 2003-12-30 Aeropharm Technology Incorporated Modulated release particles for lung delivery
AU2001278131A1 (en) 2000-08-01 2002-02-13 Shofner Engineering Associates, Inc. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002024116A1 (en) 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US20040081627A1 (en) 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
PT1920763E (pt) 2000-11-30 2014-06-25 Vectura Ltd Composições farmacêuticas para inalação
CA2432319A1 (en) 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
ES2406405T3 (es) 2000-12-27 2013-06-06 Gilead Sciences, Inc. Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
US6550472B2 (en) 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
US20030022829A1 (en) 2001-03-30 2003-01-30 Wendy Maury Novel antiviral activities primate theta defensins and mammalian cathelicidins
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6511050B2 (en) 2001-05-02 2003-01-28 Dynamo Aviation, Inc. Humidifier
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
JP2003074919A (ja) 2001-08-31 2003-03-12 Sunbow Precision Co Ltd 複合式加湿器
US20050123509A1 (en) * 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20030203930A1 (en) 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
AU2002352836B2 (en) 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
IL161446A0 (en) 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
US6851626B2 (en) 2002-01-07 2005-02-08 Aerogen, Inc. Methods and devices for nebulizing fluids
GB2384198B (en) 2002-01-18 2005-03-02 Profile Drug Delivery Ltd Nebulizer metering
GB0217199D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
US20030232019A1 (en) 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
PT2630954T (pt) 2002-03-20 2017-01-05 Civitas Therapeutics Inc Administração pulmonar de levodopa
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB0209782D0 (en) 2002-04-29 2002-06-05 Glaxo Group Ltd Medicament dispenser
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US8003080B2 (en) 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
AU2003241477A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
PT1531794T (pt) * 2002-06-28 2017-09-14 Civitas Therapeutics Inc Epinefrina inalável
US6916001B2 (en) * 2002-07-10 2005-07-12 Lowell Thomas Pugh, Jr. Concrete form apparatus and method for assembly thereof
GB0217198D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7112572B2 (en) 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
JP2006503865A (ja) 2002-09-30 2006-02-02 アキュスフィア, インコーポレイテッド 吸入のための徐放性の多孔性微粒子
CN101804200A (zh) 2002-11-22 2010-08-18 余芒 广谱抗病毒的治疗和预防
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN1194062C (zh) 2003-04-04 2005-03-23 王泽斌 一种融雪融冰组合物及其制备方法和应用
NZ543201A (en) 2003-05-01 2007-05-31 Innogene Kalbiotech Pte Ltd Lactate containing pharmaceutical composition and uses thereof
ATE501766T1 (de) 2003-05-20 2011-04-15 James F Collins Ophthalmisches arzneimittelabgabesystem
US7195179B2 (en) 2003-06-01 2007-03-27 Piezo Technologies Piezoelectric mist generation device
JP2009514779A (ja) 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
GB0324897D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0324918D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
KR20050056622A (ko) 2003-12-10 2005-06-16 주식회사 대우일렉트로닉스 플레쉬롬 다운로드 장치
WO2005067898A2 (en) 2004-01-07 2005-07-28 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
EP1713441A2 (en) 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
CA2602596A1 (en) 2004-03-30 2005-10-13 Malcolm King Compositions and methods for improved mucus function
EP1734962A4 (en) 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
US20050281740A1 (en) 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7629385B2 (en) 2004-06-29 2009-12-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Sphingolipid-derived pharmaceutical compositions
DE102004031863B3 (de) 2004-07-01 2006-03-09 Airbus Deutschland Gmbh Vorrichtung zur Fixierung von insbesondere flächenhaften Werkstücken mit einer Anlagefläche
JP2008507585A (ja) 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
JP2008512475A (ja) 2004-09-07 2008-04-24 スミスクライン・ビーチャム・コーポレイション アゴニストによるtrpv4チャネル受容体の活性化方法
US20060073173A1 (en) 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
WO2006084131A2 (en) 2005-02-01 2006-08-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection
EP2463551B1 (en) 2005-02-10 2015-04-08 BorgWarner Inc. Dual clutch transmission
WO2006102438A2 (en) 2005-03-23 2006-09-28 Ihc Intellectual Asset Management, Llc Methods and compositions for irrigation of mucosal tissues
US20060229366A1 (en) 2005-04-07 2006-10-12 Lifschitz Carlos H Method for preventing or treating respiratory infections in infants
AU2006244478B2 (en) 2005-05-05 2012-09-13 Pulmatrix Inc. Ultrasonic aerosol generator
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2900093C (en) 2005-05-18 2018-11-13 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EA016072B1 (ru) * 2005-05-18 2012-01-30 Палметрикс Инк. Применение состава соли кальция для изменения биофизических свойств слизистой оболочки
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
EP1952160B1 (en) 2005-10-31 2011-04-06 Janssen Pharmaceutica NV Methods for identifying modulators of trpv2
GB0523576D0 (en) 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
US8026233B2 (en) 2006-03-29 2011-09-27 Array Biopharma Inc. P38 inhibitors and methods of use thereof
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
EP2101748B9 (en) 2006-11-29 2015-02-25 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Use of incensole and derivatives thereof for neuroprotection and for the treatment of depression and anxiety
US8501255B2 (en) 2006-12-14 2013-08-06 Purac Biochem B.V. Particulate composition comprising calcium lactate and calcium citrate microparticles
GB0625322D0 (en) 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP2011495A1 (en) 2007-07-03 2009-01-07 Sygnis Bioscience GmbH & Co. KG Use of piperine and derivatives thereof for the therapy of neurological conditions
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
GB0719518D0 (en) 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
EP2229364B1 (en) 2007-12-05 2015-02-25 Janssen Pharmaceutica, N.V. Dibenzoazepine and dibenzooxazepine trpa1 agonists
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
NO2252275T3 (ja) 2008-02-13 2018-04-28
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
MX2010012452A (es) 2008-05-15 2011-03-15 Novartis Ag Star Suministro pulmonar de una fluoro-quinolona.
EP2323640A2 (en) 2008-08-04 2011-05-25 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods and compositions for treating neuronal damage and modulating transient receptor potential channels
GB0818476D0 (en) 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
AU2010229721A1 (en) 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
WO2010111650A2 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
KR20120002981A (ko) 2009-03-26 2012-01-09 풀매트릭스 인코퍼레이티드 호흡기 감염 치료를 위한 약제 제형 및 방법
WO2010111680A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2410984A2 (en) 2009-03-26 2012-02-01 Pulmatrix, Inc. Anti-influenza formulations and methods
US20120172429A1 (en) 2009-07-10 2012-07-05 Woolf Clifford J Permanently charged sodium and calcium channel blockers as anti- inflammatory agents
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
IL286573B (en) * 2010-09-29 2022-08-01 Pulmatrix Operating Co Inc Monovalent metallic cation dry powders for inhalation
PT106094A (pt) 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
WO2013130767A1 (en) * 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
CA3039485A1 (en) * 2016-10-14 2018-04-19 Pulmatrix Operating Company, Inc. Antifungal dry powders

Similar Documents

Publication Publication Date Title
JP2013540123A5 (ja)
RU2013118453A (ru) Катионы одновалентных металлов сухих порошков для ингаляций
RU2015146871A (ru) Сухие порошки с тиотропием
JP2016065107A5 (ja)
JP2013536845A5 (ja)
JP2019031514A5 (ja)
Newman Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases
JP2019534270A5 (ja)
JP2016512494A5 (ja)
Newman et al. Therapeutic aerosols 1--physical and practical considerations.
JP2011520911A5 (ja)
JP2016515576A5 (ja)
JP2023086774A (ja) 乾燥粉末配合および使用方法
JP2012503668A5 (ja)
JP2016527275A5 (ja)
JP2017502064A5 (ja)
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
JP2013508344A5 (ja)
RU2019114112A (ru) Противогрибковые сухие порошки
JP2012517987A5 (ja) 吸入用の医薬組成物のfpd特性を設定する方法
JP2015523395A5 (ja)
JP2013507429A5 (ja)
RU2018112077A (ru) Направленная доставка высушенных распылением композиций в легкие
JP2015519356A5 (ja)
JP2023521396A (ja) ペラミビル乾燥粉末吸入剤及びその調製方法